Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028817 | 0.84 | NR4A2 (0.43) | NR4A2CREBBPABL1MAP2K1SMN1; SMN2 | |
| SCHEMBL3030002 | 0.84 | NR4A2 (0.43) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL3027903 | 0.81 | NR4A2 (0.41) | NR4A2CREBBPMAP2K1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21060930 | 0.80 | LMNA (0.44) | NR4A2CREBBPMAP2K1ALDH1A1 | |
| SCHEMBL3033601 | 0.80 | NR4A2 (0.40) | NR4A2CREBBPMAP2K1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3554714 | 0.78 | NR4A2 (0.42) | NR4A2CREBBPALDH1A1GAASMN1; SMN2 | |
| SCHEMBL21060862 | 0.78 | XDH (0.44) | NR4A2CREBBPALDH1A1GAATSHR | |
| SCHEMBL3035913 | 0.78 | LMNA (0.44) | NR4A2CREBBPMAP2K1GAATSHR | |
| SCHEMBL16236707 | 0.77 | TDP1 (0.39) | NR4A2CREBBPGAASMN1; SMN2 | |
| SCHEMBL3032676 | 0.75 | PYGL (0.42) | NR4A2CREBBPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | NR4A2 2805/4885CREBBP 2208/4885CCNC 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.